ozanimod vs Ponesimod

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: S1P receptor · full Ulcerative Colitis pipeline

ozanimod · Zeposia

Marketed by Bristol-Myers Squibb and partners

Approved in Ulcerative ColitisSmall molecule (S1P1,5 modulator)
Reliable signal

NCT02435992 · Phase 3 · completed

Randomized, quadruple-blinded, placebo-controlled, large adequately powered Phase 3 trial (n=1012) with a hard clinical/endoscopic remission endpoint that achieved statistical significance in the favorable direction at both induction and maintenance timepoints, satisfying the 'strong' definition.

Next expected readout: July 2032 · NCT05076175 (registry estimate)

Reported efficacy

Percentage of Participants in Clinical Remission at 10 Weeks; Percentage of Participants in Clinical Remission at 52 Weeks: Percentage of Participants in Clinical Remission at 10 Weeks (At 10 Weeks): RPC1063 Cohort 1(Induction Period) 18.4% vs Placebo Cohort 1 (Induction Period) 6.0% vs RPC1063 Cohort 2 (Induction Period) 21.0%; p=0.0001 (RPC1063 Cohort 1(Induction Period) vs Placebo Cohort 1 (Induction Period)) (met)

Result source: NCT02435992

Ponesimod

Marketed by Vanda Pharmaceuticals and partners

Phase 3 in Ulcerative Colitissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: April 2029 · NCT07686081 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointozanimodPonesimod
Clinical remission (induction)18.4% vs 6%+12.4 vs placebowk 10 · n 429NCT02435992
3 other results
  • 21% vs 6% wk 10 · n 367 · Phase 3 · primary NCT02435992
  • 16.4% vs 6.2% 1 mg · wk 8 · n 67 · Phase 2 · primary NCT01647516
  • 13.8% vs 6.2% 0.5 mg · wk 8 · n 65 · Phase 2 · primary NCT01647516
—Trial running · NCT07686081
Clinical remission (maintenance)37% vs 18.5%+18.5 vs placebowk 52 · n 230NCT02435992
2 other results
  • 20.9% vs 6.2% 1 mg · wk 32 · n 67 · Phase 2 · secondary NCT01647516
  • 26.2% vs 6.2% 0.5 mg · wk 32 · n 65 · Phase 2 · secondary NCT01647516
—Trial running · NCT07686081
Clinical response (induction)47.8% vs 25.9%+21.9 vs placebowk 10 · n 429NCT02435992
3 other results
  • 52.6% vs 25.9% wk 10 · n 367 · Phase 3 · secondary NCT02435992
  • 56.7% vs 36.9% 1 mg · wk 8 · n 67 · Phase 2 · secondary NCT01647516
  • 53.8% vs 36.9% 0.5 mg · wk 8 · n 65 · Phase 2 · secondary NCT01647516
—Trial running · NCT07686081
Endoscopic improvement (induction)27.3% vs 11.6%+15.7 vs placebowk 10 · n 429NCT02435992
3 other results
  • 27.2% vs 11.6% wk 10 · n 367 · Phase 3 · secondary NCT02435992
  • 34.3% vs 12.3% 1 mg · wk 8 · n 67 · Phase 2 · secondary NCT01647516
  • 27.7% vs 12.3% 0.5 mg · wk 8 · n 65 · Phase 2 · secondary NCT01647516
—Trial running · NCT07686081
Corticosteroid-free remission (maintenance)31.7% vs 16.7%+15 vs placebowk 52 · n 230NCT02435992—Trial running · NCT07686081

Clinical remission (induction)

ozanimod
18.4% vs 6%+12.4 vs placebowk 10 · n 429NCT02435992
3 other results
  • 21% vs 6% wk 10 · n 367 · Phase 3 · primary NCT02435992
  • 16.4% vs 6.2% 1 mg · wk 8 · n 67 · Phase 2 · primary NCT01647516
  • 13.8% vs 6.2% 0.5 mg · wk 8 · n 65 · Phase 2 · primary NCT01647516
Ponesimod
—Trial running · NCT07686081

Clinical remission (maintenance)

ozanimod
37% vs 18.5%+18.5 vs placebowk 52 · n 230NCT02435992
2 other results
  • 20.9% vs 6.2% 1 mg · wk 32 · n 67 · Phase 2 · secondary NCT01647516
  • 26.2% vs 6.2% 0.5 mg · wk 32 · n 65 · Phase 2 · secondary NCT01647516
Ponesimod
—Trial running · NCT07686081

Clinical response (induction)

ozanimod
47.8% vs 25.9%+21.9 vs placebowk 10 · n 429NCT02435992
3 other results
  • 52.6% vs 25.9% wk 10 · n 367 · Phase 3 · secondary NCT02435992
  • 56.7% vs 36.9% 1 mg · wk 8 · n 67 · Phase 2 · secondary NCT01647516
  • 53.8% vs 36.9% 0.5 mg · wk 8 · n 65 · Phase 2 · secondary NCT01647516
Ponesimod
—Trial running · NCT07686081

Endoscopic improvement (induction)

ozanimod
27.3% vs 11.6%+15.7 vs placebowk 10 · n 429NCT02435992
3 other results
  • 27.2% vs 11.6% wk 10 · n 367 · Phase 3 · secondary NCT02435992
  • 34.3% vs 12.3% 1 mg · wk 8 · n 67 · Phase 2 · secondary NCT01647516
  • 27.7% vs 12.3% 0.5 mg · wk 8 · n 65 · Phase 2 · secondary NCT01647516
Ponesimod
—Trial running · NCT07686081

Corticosteroid-free remission (maintenance)

ozanimod
31.7% vs 16.7%+15 vs placebowk 52 · n 230NCT02435992
Ponesimod
—Trial running · NCT07686081
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Ponesimod: no structured comparison results are available for Ulcerative Colitis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. ozanimod: 4 of 4 rows · Ponesimod: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricozanimod
Dropout rate
—1mga
NCT02435992 · Phase 3 · monotherapy
show 15 more results
—1mg
NCT02435992 · Phase 3 · monotherapy
—1mg
NCT02435992 · Phase 3 · monotherapy
—RPC1063 (Maintenance Period)
NCT02435992 · Phase 3 · monotherapy
11.7%RPC1063 Cohort 2 (Induction Period
NCT02435992 · Phase 3 · monotherapy
46.3%RPC01-202 Ozanimod Open Label
NCT02531126 · Phase 3 · monotherapy
69.5%RPC01-3101 Ozanimod-Ozanimod
NCT02531126 · Phase 3 · monotherapy
—1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
6%1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—0.5 mg/1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
4.5%0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—Open-Label Treatment Period (OLP):
NCT01647516 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—1mga
NCT02435992 · Phase 3 · monotherapy
show 15 more results
—1mg
NCT02435992 · Phase 3 · monotherapy
—1mg
NCT02435992 · Phase 3 · monotherapy
—RPC1063 (Maintenance Period)
NCT02435992 · Phase 3 · monotherapy
3.3%RPC1063 Cohort 2 (Induction Period
NCT02435992 · Phase 3 · monotherapy
7.4%RPC01-202 Ozanimod Open Label
NCT02531126 · Phase 3 · monotherapy
6.1%RPC01-3101 Ozanimod-Ozanimod
NCT02531126 · Phase 3 · monotherapy
—1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
0%1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—0.5 mg/1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
3%0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—Open-Label Treatment Period (OLP):
NCT01647516 · Phase 2 · registry result, not featured evidence
Serious AEs
4%1mga
NCT02435992 · Phase 3 · monotherapy
show 15 more results
6.3%1mg
NCT02435992 · Phase 3 · monotherapy
5.2%1mg
NCT02435992 · Phase 3 · monotherapy
—RPC1063 (Maintenance Period)
NCT02435992 · Phase 3 · monotherapy
—RPC1063 Cohort 2 (Induction Period
NCT02435992 · Phase 3 · monotherapy
14.8%RPC01-202 Ozanimod Open Label
NCT02531126 · Phase 3 · monotherapy
17.2%RPC01-3101 Ozanimod-Ozanimod
NCT02531126 · Phase 3 · monotherapy
3%1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
2.4%1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
18.6%1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
1.5%0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
0%0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
25%0.5 mg/1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
9.1%Open-Label Treatment Period (OLP):
NCT01647516 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
1mga
anaemia 3.5% (placebo 6%)
NCT02435992 · Phase 3 · monotherapy
show 11 more results
1mg
anaemia 4.1% (placebo 6%)
NCT02435992 · Phase 3 · monotherapy
1mg
anaemia 0.9% (placebo 6%)
NCT02435992 · Phase 3 · monotherapy
covid-19 25.9% (placebo 16.8%)
lymphopenia 16.7% (placebo 17.3%)
leukopenia 7.4% (placebo 4.1%)
NCT02531126 · Phase 3 · monotherapy
lymphopenia 16.3% (placebo 17.3%)
covid-19 11.3% (placebo 16.8%)
lymphocyte count decreased 10.8% (placebo 12.8%)
NCT02531126 · Phase 3 · monotherapy
1 mg
alanine aminotransferase increased 3% (placebo 0%)
headache 3% (placebo 4.6%)
anaemia 1.5% (placebo 6.2%)
NCT01647516 · Phase 2 · registry result, not featured evidence
1 mg
alanine aminotransferase increased 2.4% (placebo 0%)
colitis ulcerative 2.4% (placebo 1.5%)
anaemia 0% (placebo 6.2%)
NCT01647516 · Phase 2 · registry result, not featured evidence
1 mg
hypertension 11.9% (placebo 0%)
gamma-glutamyltransferase increased 8.5% (placebo 0%)
upper respiratory tract infection 8.5% (placebo 3.1%)
NCT01647516 · Phase 2 · registry result, not featured evidence
0.5 mg
anaemia 6.2% (placebo 6.2%)
colitis ulcerative 3.1% (placebo 1.5%)
back pain 1.5% (placebo 1.5%)
NCT01647516 · Phase 2 · registry result, not featured evidence
0.5 mg
alanine aminotransferase increased 2.8% (placebo 0%)
nasopharyngitis 2.8% (placebo 0%)
anaemia 0% (placebo 6.2%)
NCT01647516 · Phase 2 · registry result, not featured evidence
0.5 mg/1 mg
anaemia 5.4% (placebo 6.2%)
gamma-glutamyltransferase increased 5.4% (placebo 0%)
lymphocyte count decreased 5.4% (placebo 0%)
NCT01647516 · Phase 2 · registry result, not featured evidence
anaemia 7.3% (placebo 6.2%)
colitis ulcerative 7.3% (placebo 1.5%)
bronchitis 5.5% (placebo 0%)
NCT01647516 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

ozanimod

Clinical Remission 16.4% (n=67) vs 6.2% (n=65) placebo @ 8wk1 mg
responder rate · % of participants
NCT01647516 · Phase 2 · registry result, not featured evidence
show 6 more results
20.9% (n=67) vs 6.2% (n=65) placebo @ 32wk1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
13.8% (n=65) vs 6.2% (n=65) placebo @ 8wk0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
26.2% (n=65) vs 6.2% (n=65) placebo @ 32wk0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
18.4% (n=429) vs 6% (n=216) placebo @ 10wk
NCT02435992 · Phase 3 · monotherapy
21% (n=367) vs 6% (n=216) placebo @ 10wk
NCT02435992 · Phase 3 · monotherapy
37% (n=230) vs 24.6% (n=69) placebo @ 52wk
NCT02435992 · Phase 3 · monotherapy
Clinical Response 56.7% (n=67) vs 36.9% (n=65) placebo @ 8wk1 mg
responder rate · % of participants
NCT01647516 · Phase 2 · registry result, not featured evidence
show 6 more results
50.7% (n=67) vs 20% (n=65) placebo @ 32wk1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
53.8% (n=65) vs 36.9% (n=65) placebo @ 8wk0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
35.4% (n=65) vs 20% (n=65) placebo @ 32wk0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
47.8% (n=429) vs 25.9% (n=216) placebo @ 10wk
NCT02435992 · Phase 3 · monotherapy
52.6% (n=367) vs 25.9% (n=216) placebo @ 10wk
NCT02435992 · Phase 3 · monotherapy
60% (n=230) vs 39.1% (n=69) placebo @ 52wk
NCT02435992 · Phase 3 · monotherapy
Endoscopic Improvement 34.3% (n=67) vs 12.3% (n=65) placebo @ 8wk1 mg
responder rate · % of participants
NCT01647516 · Phase 2 · registry result, not featured evidence
show 6 more results
32.8% (n=67) vs 12.3% (n=65) placebo @ 32wk1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
27.7% (n=65) vs 12.3% (n=65) placebo @ 8wk0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
32.3% (n=65) vs 12.3% (n=65) placebo @ 32wk0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
27.3% (n=429) vs 11.6% (n=216) placebo @ 10wk
NCT02435992 · Phase 3 · monotherapy
27.2% (n=367) vs 11.6% (n=216) placebo @ 10wk
NCT02435992 · Phase 3 · monotherapy
45.7% (n=230) vs 29% (n=69) placebo @ 52wk
NCT02435992 · Phase 3 · monotherapy
Mucosal Healing 12.6% (n=429) vs 3.7% (n=216) placebo @ 10wk
responder rate · % of participants
NCT02435992 · Phase 3 · monotherapy
show 2 more results
11.4% (n=367) vs 3.7% (n=216) placebo @ 10wk
NCT02435992 · Phase 3 · monotherapy
29.6% (n=230) vs 10.1% (n=69) placebo @ 52wk
NCT02435992 · Phase 3 · monotherapy
Corticosteroid-free Clinical Remission 31.7% (n=230) vs 24.6% (n=69) placebo @ 52wk
responder rate · % of participants
NCT02435992 · Phase 3 · monotherapy
Durable Clinical Remission 17.8% (n=230) vs 7.2% (n=69) placebo @ 52wk
responder rate · % of participants
NCT02435992 · Phase 3 · monotherapy
Clinical Remission 44% (n=266) vs 41.6% (n=113) placebo @ 46wk
responder rate · % of participants
Extension (open-label)
NCT02531126 · Phase 3 · monotherapy
show 4 more results
50.5% (n=266) vs 57.8% (n=113) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
50.9% (n=266) vs 59.4% (n=113) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
54.7% (n=266) vs 39.1% (n=113) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
54.5% (n=266) vs 38.5% (n=113) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy
Clinical Response 77% (n=261) vs 81.8% (n=110) placebo @ 46wk
responder rate · % of participants
Extension (open-label)
NCT02531126 · Phase 3 · monotherapy
show 4 more results
83.9% (n=261) vs 84.1% (n=110) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
87.6% (n=261) vs 89.6% (n=110) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
86.4% (n=261) vs 82.2% (n=110) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
90.1% (n=261) vs 74.4% (n=110) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy
Endoscopic Improvement 49.7% (n=290) vs 51.2% (n=121) placebo @ 46wk
responder rate · % of participants
Extension (open-label)
NCT02531126 · Phase 3 · monotherapy
show 9 more results
41.4% (n=30) vs 51.2% (n=121) placebo @ 46wk
NCT02531126 · Phase 3 · monotherapy
58.6% (n=290) vs 60.6% (n=121) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
50% (n=30) vs 60.6% (n=121) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
60.8% (n=290) vs 61.1% (n=121) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
57.7% (n=30) vs 61.1% (n=121) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
62.5% (n=290) vs 49.1% (n=121) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
56.3% (n=30) vs 49.1% (n=121) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
60.9% (n=290) vs 43.5% (n=121) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy
100% (n=30) vs 43.5% (n=121) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy
Corticosteroid-free Clinical Remission 38% (n=266) vs 40.7% (n=113) placebo @ 46wk
responder rate · % of participants
Extension (open-label)
NCT02531126 · Phase 3 · monotherapy
show 4 more results
41.6% (n=266) vs 52.2% (n=113) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
45.1% (n=266) vs 55.1% (n=113) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
47.3% (n=266) vs 37% (n=113) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
48.2% (n=266) vs 38.5% (n=113) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy
Histologic Remission 25.4% (n=276) vs 19.4% (n=108) placebo @ 46wk
responder rate · % of participants
Extension (open-label)
NCT02531126 · Phase 3 · monotherapy
show 9 more results
48.1% (n=30) vs 19.4% (n=108) placebo @ 46wk
NCT02531126 · Phase 3 · monotherapy
32.8% (n=276) vs 22.6% (n=108) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
26.7% (n=30) vs 22.6% (n=108) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
32.4% (n=276) vs 32.9% (n=108) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
48% (n=30) vs 32.9% (n=108) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
47.5% (n=276) vs 42.9% (n=108) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
62.5% (n=30) vs 42.9% (n=108) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
56.1% (n=276) vs 34.1% (n=108) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy
100% (n=30) vs 34.1% (n=108) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy
Mucosal Healing 20.4% (n=276) vs 14.8% (n=108) placebo @ 46wk
responder rate · % of participants
Extension (open-label)
NCT02531126 · Phase 3 · monotherapy
show 9 more results
25.9% (n=30) vs 14.8% (n=108) placebo @ 46wk
NCT02531126 · Phase 3 · monotherapy
28% (n=276) vs 19% (n=108) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
20% (n=30) vs 19% (n=108) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
27.4% (n=276) vs 32.8% (n=108) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
44% (n=30) vs 32.8% (n=108) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
43.9% (n=276) vs 32.7% (n=108) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
37.5% (n=30) vs 32.7% (n=108) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
46.3% (n=276) vs 26.8% (n=108) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy
100% (n=30) vs 26.8% (n=108) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy

+ 6 further endpoints in the CSV export.

Multiple Sclerosis

Shared mechanism: S1P receptor · full Multiple Sclerosis pipeline

ozanimod · Zeposia

Marketed by Bristol-Myers Squibb and partners

Approved in Multiple SclerosisSmall molecule (S1P1,5 modulator)
Partial signal

NCT01628393 · Phase 2/3 · completed

The trial was randomized, placebo-controlled and fully blinded in 258 participants, and both ozanimod doses significantly reduced new brain lesions on MRI versus placebo. Because the primary measure was an imaging biomarker rather than a clinical outcome such as relapse rate or disability, this trial supports but does not on its own confirm a clinical benefit.

Next expected readout: August 2028 · NCT06529406 (registry estimate)

Reported efficacy

Adjusted Annualized Relapse Rate (ARR) at the End of Month 24: Adjusted annualized relapse rate (ARR) over 24 months (RADIANCE): 0.17 ozanimod 1.0mg, 0.22 ozanimod 0.5mg, vs 0.28 interferon beta-1a; rate ratio vs interferon 0.62 (p<0.0001) for the 1.0mg dose and 0.79 (p=0.0167) for the 0.5mg dose (met)

Result source: NCT02047734

Ponesimod

Marketed by Vanda Pharmaceuticals and partners

Approved in Multiple Sclerosissmall molecule
Reliable signal

NCT02425644 · Phase 3 · completed

This large, randomized, double-blind trial compared ponesimod head-to-head against an approved active comparator (teriflunomide) using relapse rate, a core clinical measure of multiple sclerosis activity, and ponesimod met its primary endpoint with a statistically significant roughly 30% relative reduction in relapses.

Reported efficacy

Annualized Confirmed Relapse Rate (From randomization to end of study (Week 108)): Annualized relapse rate at week 108: 0.202 ponesimod vs 0.290 teriflunomide; rate ratio 0.695 (99% CI 0.536-0.902); 30.5% relative reduction; P<.001. (met)

Result source: NCT02425644

Results for Multiple Sclerosis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointozanimodPonesimod
Annualised relapse rate0.2 vs 0.3vs Interferon Beta-1a1 mg · wk 96 · n 433NCT02047734
5 other results
  • 0.2 vs 0.3 1 mg · wk 52 · n 447 · Phase 3 · primary NCT02294058
  • 0.2 vs 0.3 0.5 mg · wk 96 · n 439 · Phase 3 · primary NCT02047734
  • 0.2 vs 0.3 0.5 mg · wk 52 · n 451 · Phase 3 · primary NCT02294058
  • 0.2 vs 0.5 1 mg · wk 24 · n 83 · Phase 2/3 · secondary NCT01628393
  • 0.3 vs 0.5 0.5 mg · wk 24 · n 87 · Phase 2/3 · secondary NCT01628393
0.2 vs 0.3vs Teriflunomide20 mg · wk 108 · n 567NCT02425644
Free of 3-month confirmed disability progression (%)—Trial running · NCT06408259—Not reported
New or enlarging T2 lesions0.8 vs 9−8.2 vs placebo1 mg · wk 24 · n 83NCT01628393
1 other result
  • 1.4 vs 9 0.5 mg · wk 24 · n 87 · Phase 2/3 · secondary NCT01628393
—Not reported

Annualised relapse rate

ozanimod
0.2 vs 0.3vs Interferon Beta-1a1 mg · wk 96 · n 433NCT02047734
5 other results
  • 0.2 vs 0.3 1 mg · wk 52 · n 447 · Phase 3 · primary NCT02294058
  • 0.2 vs 0.3 0.5 mg · wk 96 · n 439 · Phase 3 · primary NCT02047734
  • 0.2 vs 0.3 0.5 mg · wk 52 · n 451 · Phase 3 · primary NCT02294058
  • 0.2 vs 0.5 1 mg · wk 24 · n 83 · Phase 2/3 · secondary NCT01628393
  • 0.3 vs 0.5 0.5 mg · wk 24 · n 87 · Phase 2/3 · secondary NCT01628393
Ponesimod
0.2 vs 0.3vs Teriflunomide20 mg · wk 108 · n 567NCT02425644

Free of 3-month confirmed disability progression (%)

ozanimod
—Trial running · NCT06408259
Ponesimod
—Not reported

New or enlarging T2 lesions

ozanimod
0.8 vs 9−8.2 vs placebo1 mg · wk 24 · n 83NCT01628393
1 other result
  • 1.4 vs 9 0.5 mg · wk 24 · n 87 · Phase 2/3 · secondary NCT01628393
Ponesimod
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. ozanimod: 6 of 6 rows · Ponesimod: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricozanimod
Rows use multiple source trials
Ponesimod
Rows use multiple source trials
Brain Volume
percent change · % of baseline
Extension (open-label)
-1.922% (n=623) vs -1.889% (n=596) IFN-B-1a @ 312wk1.0 mga,b,c,d
NCT02576717 · Phase 3 · registry result, not featured evidence
show 1 more dose
-1.696% (n=611) vs -1.889% (n=596) IFN-B-1a @ 312wk0.5 mg
NCT02576717 · Phase 3 · registry result, not featured evidence
-2.52% (n=196) vs -2.72% (n=193) Teriflunomide then Ponesimod20 mgb,c,d
NCT03232073 · Phase 3 · registry result, not featured evidence
Time to First Relapse
time to event · months
Extension (open-label)
NA vs NA IFN-B-1a months1.0 mga,b,c,d
NCT02576717 · Phase 3 · registry result, not featured evidence
show 1 more dose
NA vs NA IFN-B-1a months0.5 mg
NCT02576717 · Phase 3 · registry result, not featured evidence
92.93 vs NA Teriflunomide then Ponesimod months*20 mgb,c,d
NCT03232073 · Phase 3 · registry result, not featured evidence · converted to months from 402.71 weeks as posted
Dropout rate
—1.0 mge
NCT01628393 · Phase 2/3
show 11 more results
1.2%1 mg
NCT01628393 · Phase 2/3
—1.0 mg
NCT01628393 · Phase 2/3
—0.5 mg
NCT01628393 · Phase 2/3
2.3%0.5 mg
NCT01628393 · Phase 2/3
—0.5 mg
NCT01628393 · Phase 2/3
10.6%1 mg
NCT02047734 · Phase 3
15.6%0.5 mg
NCT02047734 · Phase 3
6.5%1 mg
NCT02294058 · Phase 3
5.8%0.5 mg
NCT02294058 · Phase 3
20.9%1.0 mg
NCT02576717 · Phase 3 · registry result, not featured evidence
21%0.5 mg
NCT02576717 · Phase 3 · registry result, not featured evidence
13.6%20 mge
NCT02425644 · Phase 3
show 4 more results
19.8%20 mg
NCT03232073 · Phase 3 · registry result, not featured evidence
33.9%20 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
35%40 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
38.3%10 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—1.0 mge
NCT01628393 · Phase 2/3
show 11 more results
—1 mg
NCT01628393 · Phase 2/3
—1.0 mg
NCT01628393 · Phase 2/3
—0.5 mg
NCT01628393 · Phase 2/3
—0.5 mg
NCT01628393 · Phase 2/3
—0.5 mg
NCT01628393 · Phase 2/3
3%1 mg
NCT02047734 · Phase 3
2.9%0.5 mg
NCT02047734 · Phase 3
2.9%1 mg
NCT02294058 · Phase 3
1.6%0.5 mg
NCT02294058 · Phase 3
3%1.0 mg
NCT02576717 · Phase 3 · registry result, not featured evidence
3.7%0.5 mg
NCT02576717 · Phase 3 · registry result, not featured evidence
2.3%20 mge
NCT02425644 · Phase 3
show 4 more results
1.6%20 mg
NCT03232073 · Phase 3 · registry result, not featured evidence
0.8%20 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
3.4%40 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
1.7%10 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
Serious AEs
7.3%1.0 mge
NCT01628393 · Phase 2/3
show 11 more results
—1 mg
NCT01628393 · Phase 2/3
0%1.0 mg
NCT01628393 · Phase 2/3
7.9%0.5 mg
NCT01628393 · Phase 2/3
—0.5 mg
NCT01628393 · Phase 2/3
3.4%0.5 mg
NCT01628393 · Phase 2/3
6.5%1 mg
NCT02047734 · Phase 3
7.1%0.5 mg
NCT02047734 · Phase 3
2.9%1 mg
NCT02294058 · Phase 3
3.5%0.5 mg
NCT02294058 · Phase 3
15.5%1.0 mg
NCT02576717 · Phase 3 · registry result, not featured evidence
15.7%0.5 mg
NCT02576717 · Phase 3 · registry result, not featured evidence
8.7%20 mge
NCT02425644 · Phase 3
show 4 more results
12.8%20 mg
NCT03232073 · Phase 3 · registry result, not featured evidence
24.1%20 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
16.6%40 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
23%10 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
1.0 mge
nasopharyngitis 13.8% (placebo 13.6%)
alanine aminotransferase increased 9.8% (placebo 0%)
upper respiratory tract infection 8.9% (placebo 3.4%)
NCT01628393 · Phase 2/3
show 9 more results
1.0 mg
gamma-glutamyltransferase increased 6% (placebo 0%)
nasopharyngitis 6% (placebo 13.6%)
alanine aminotransferase increased 4.8% (placebo 0%)
NCT01628393 · Phase 2/3
0.5 mg
upper respiratory tract infection 15.9% (placebo 3.4%)
nasopharyngitis 13.5% (placebo 13.6%)
gamma-glutamyltransferase increased 8.7% (placebo 0%)
NCT01628393 · Phase 2/3
0.5 mg
nasopharyngitis 12.6% (placebo 13.6%)
urinary tract infection 6.9% (placebo 2.3%)
back pain 5.7% (placebo 10.2%)
NCT01628393 · Phase 2/3
1 mg
nasopharyngitis 15.7%
headache 10.1%
upper respiratory tract infection 7.8%
NCT02047734 · Phase 3
0.5 mg
nasopharyngitis 13.4%
headache 12.5%
upper respiratory tract infection 8.2%
NCT02047734 · Phase 3
1 mg
headache 7.6%
nasopharyngitis 6.7%
upper respiratory tract infection 4%
NCT02294058 · Phase 3
0.5 mg
nasopharyngitis 9.7%
upper respiratory tract infection 6.8%
headache 6%
NCT02294058 · Phase 3
1.0 mg
nasopharyngitis 20.9% (placebo 13.5%)
headache 17% (placebo 5.4%)
covid-19 16.1% (placebo 21.6%)
NCT02576717 · Phase 3 · registry result, not featured evidence
0.5 mg
nasopharyngitis 21% (placebo 13.5%)
headache 16.9% (placebo 5.4%)
covid-19 15.5% (placebo 21.6%)
NCT02576717 · Phase 3 · registry result, not featured evidence
20 mge
alanine aminotransferase increased 19.5%
nasopharyngitis 19.3%
headache 11.3%
NCT02425644 · Phase 3
show 4 more results
20 mg
covid-19 26.2%
nasopharyngitis 18.7%
alanine aminotransferase increased 16.6%
NCT03232073 · Phase 3 · registry result, not featured evidence
20 mg
nasopharyngitis 31.7%
headache 21.4%
upper respiratory tract infection 19.3%
NCT01093326 · Phase 2 · registry result, not featured evidence
40 mg
nasopharyngitis 29.8%
headache 27.2%
upper respiratory tract infection 25.8%
NCT01093326 · Phase 2 · registry result, not featured evidence
10 mg
nasopharyngitis 33.1%
headache 27.3%
upper respiratory tract infection 19.4%
NCT01093326 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dThe assessment timepoint is not available for both results.
  5. ePopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

ozanimod

Gadolinium Enhancing Lesion 1.5 vs 11.1 placebo lesions @ 24wk1 mg
event count · lesions
NCT01628393 · Phase 2/3
show 7 more results
0.2 vs 3.2 placebo lesions @ 24wk1 mg
NCT01628393 · Phase 2/3
0.176 vs 0.373 Interferon Beta-1a lesions @ 96wk1 mg
NCT02047734 · Phase 3
0.16 vs 0.433 Interferon Beta-1a lesions @ 52wk1 mg
NCT02294058 · Phase 3
1.9 vs 11.1 placebo lesions @ 24wk0.5 mg
NCT01628393 · Phase 2/3
0.4 vs 3.2 placebo lesions @ 24wk0.5 mg
NCT01628393 · Phase 2/3
0.197 vs 0.373 Interferon Beta-1a lesions @ 96wk0.5 mg
NCT02047734 · Phase 3
0.287 vs 0.433 Interferon Beta-1a lesions @ 52wk0.5 mg
NCT02294058 · Phase 3
New or Enlarging T2 Lesion 0.8 vs 9 placebo lesions @ 24wk1 mg
event count · lesions
NCT01628393 · Phase 2/3
show 1 more result
1.4 vs 9 placebo lesions @ 24wk0.5 mg
NCT01628393 · Phase 2/3
New or Enlarging T2 Lesion 1.835 vs 3.183 Interferon Beta-1a lesions/scan @ 96wk1 mg
event count · lesions/scan
NCT02047734 · Phase 3
show 1 more result
2.092 vs 3.183 Interferon Beta-1a lesions/scan @ 96wk0.5 mg
NCT02047734 · Phase 3
Time to 3m Confirmed Disability Worsening NA vs NA Interferon Beta-1a months1 mg
time to event · months
NCT02047734 · Phase 3
show 3 more results
NA vs NA Interferon Beta-1a months1 mg
NCT02294058 · Phase 3
NA vs NA Interferon Beta-1a months0.5 mg
NCT02047734 · Phase 3
NA vs NA Interferon Beta-1a months0.5 mg
NCT02294058 · Phase 3
Time to 6m Confirmed Disability Worsening NA vs NA Interferon Beta-1a months1 mg
time to event · months
NCT02047734 · Phase 3
show 3 more results
NA vs NA Interferon Beta-1a months1 mg
NCT02294058 · Phase 3
NA vs NA Interferon Beta-1a months0.5 mg
NCT02047734 · Phase 3
NA vs NA Interferon Beta-1a months0.5 mg
NCT02294058 · Phase 3
MRI Gadolinium Lesion-Free 65.6% (n=433) vs 56.2% (n=441) Interferon Beta-1a @ 96wk1 mg
responder rate · % of participants
NCT02047734 · Phase 3
show 3 more results
74.05% (n=447) vs 63.17% (n=448) Interferon Beta-1a @ 52wk1 mg
NCT02294058 · Phase 3
63.3% (n=439) vs 56.2% (n=441) Interferon Beta-1a @ 96wk0.5 mg
NCT02047734 · Phase 3
68.29% (n=451) vs 63.17% (n=448) Interferon Beta-1a @ 52wk0.5 mg
NCT02294058 · Phase 3
no New or Enlarged T2 Lesion 23.8% (n=433) vs 18.4% (n=441) Interferon Beta-1a @ 96wk1 mg
responder rate · % of participants
NCT02047734 · Phase 3
show 1 more result
23.5% (n=439) vs 18.4% (n=441) Interferon Beta-1a @ 96wk0.5 mg
NCT02047734 · Phase 3
Whole Brain Volume -0.707% (n=390) vs -0.937% (n=397) Interferon Beta-1a @ 96wk1 mg
percent change · % of baseline
NCT02047734 · Phase 3
show 3 more results
-0.69% (n=271) vs -0.94% (n=279) Interferon Beta-1a @ 96wk1 mg
NCT02047734 · Phase 3
-0.707% (n=398) vs -0.937% (n=397) Interferon Beta-1a @ 96wk0.5 mg
NCT02047734 · Phase 3
-0.71% (n=274) vs -0.94% (n=279) Interferon Beta-1a @ 96wk0.5 mg
NCT02047734 · Phase 3
MSFC -0.01 vs -0.052 Interferon Beta-1a Z-score @ 96wk1 mg
absolute change · Z-score
NCT02047734 · Phase 3
show 3 more results
0.003 vs -0.022 Interferon Beta-1a Z-score @ 52wk1 mg
NCT02294058 · Phase 3
0.036 vs -0.052 Interferon Beta-1a Z-score @ 96wk0.5 mg
NCT02047734 · Phase 3
-0.007 vs -0.022 Interferon Beta-1a Z-score @ 52wk0.5 mg
NCT02294058 · Phase 3
New or Enlarging T2 Lesion 1.465 vs 2.836 Interferon Beta-1a T2 lesions/scan @ 52wk1 mg
event count · T2 lesions/scan
NCT02294058 · Phase 3
show 1 more result
2.139 vs 2.836 Interferon Beta-1a T2 lesions/scan @ 52wk0.5 mg
NCT02294058 · Phase 3
MRI T2 Lesion-Free 27.96% (n=447) vs 23.44% (n=448) Interferon Beta-1a @ 52wk1 mg
responder rate · % of participants
NCT02294058 · Phase 3
show 1 more result
26.39% (n=451) vs 23.44% (n=448) Interferon Beta-1a @ 52wk0.5 mg
NCT02294058 · Phase 3
Brain Volume -0.39% (n=338) vs -0.57% (n=334) Interferon Beta-1a @ 52wk1 mg
percent change · % of baseline
NCT02294058 · Phase 3
show 1 more result
-0.5% (n=347) vs -0.57% (n=334) Interferon Beta-1a @ 52wk0.5 mg
NCT02294058 · Phase 3

+ 20 further endpoints in the CSV export.

Ponesimod

FSIQ-RMS Symptoms Domain -0.01 vs 3.56 Teriflunomide score @ 108wk20 mg
absolute change · score
NCT02425644 · Phase 3
CUAL Rate Annualized 1.405 vs 3.164 Teriflunomide per year @ 108wk20 mg
event rate · per year
NCT02425644 · Phase 3
Confirmed Disability Progression 12w 7.6% (n=567) vs 8.3% (n=566) Teriflunomide @ 60wk20 mg
responder rate · % of participants
NCT02425644 · Phase 3
show 1 more result
10.8% (n=567) vs 13.2% (n=566) Teriflunomide @ 108wk20 mg
NCT02425644 · Phase 3
Confirmed Disability Progression 24w 6.3% (n=567) vs 6.9% (n=566) Teriflunomide @ 60wk20 mg
responder rate · % of participants
NCT02425644 · Phase 3
show 1 more result
8.7% (n=567) vs 10.5% (n=566) Teriflunomide @ 108wk20 mg
NCT02425644 · Phase 3
Annualized Relapse 0.143 vs 0.184 Teriflunomide then Ponesimod per year20 mg
event rate · per year
Extension (open-label)
NCT03232073 · Phase 3 · registry result, not featured evidence
Time to 3m Confirmed Disability Worsening NA vs NA Teriflunomide then Ponesimod months20 mg
time to event · months
Extension (open-label)
NCT03232073 · Phase 3 · registry result, not featured evidence
Time to CDP 6mo NA vs NA Teriflunomide then Ponesimod months20 mg
time to event · months
Extension (open-label)
NCT03232073 · Phase 3 · registry result, not featured evidence
Relapse Free 56.7% (n=439) vs 51.6% (n=438) Teriflunomide then Ponesimod20 mg
responder rate · % of participants
Extension (open-label)
NCT03232073 · Phase 3 · registry result, not featured evidence
EDSS 0.16 vs 0.34 Teriflunomide then Ponesimod score20 mg
absolute change · score
Extension (open-label)
NCT03232073 · Phase 3 · registry result, not featured evidence
NEDA 17.5% (n=439) vs 7.5% (n=436) Teriflunomide then Ponesimod20 mg
responder rate · % of participants
Extension (open-label)
NCT03232073 · Phase 3 · registry result, not featured evidence
NEDA-4 5.2% (n=437) vs 2.3% (n=435) Teriflunomide then Ponesimod20 mg
responder rate · % of participants
Extension (open-label)
NCT03232073 · Phase 3 · registry result, not featured evidence
CUAL Rate Annualized 1.352% (n=438) vs 1.954% (n=435) Teriflunomide then Ponesimod20 mg
event rate · % of participants
Extension (open-label)
NCT03232073 · Phase 3 · registry result, not featured evidence

+ 8 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ozanimod's landscape · Ponesimod's landscape